Results from a randomized, double-blind, placebo-controlled, exploratory, multicenter study of GBR 830 in adult patients with moderate-to-severe atopic dermatitis

Double Blind ◽

Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.11 ◽

2021 ◽

Vol 5 (1) ◽

pp. s11

Author(s):

Eric Simpson ◽

Joseph Merola ◽

Jonathan Silverberg ◽

Rebecca Zachariae ◽

Rebecca Olsen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pooled Analysis ◽

Adult Patients ◽

Phase 2 ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Abstract not available.

26292 Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.402 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB96

Author(s):

David Rosmarin ◽

Scott Fretzin ◽

Lindsay Strowd ◽

Marta Casillas ◽

Amy DeLozier ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Rapid Improvement ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Skin Pain

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study

British Journal of Dermatology ◽

10.1111/bjd.20690 ◽

2021 ◽

Author(s):

Y. Zhao ◽

L. Wu ◽

Q. Lu ◽

X. Gao ◽

X. Zhu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2013.12.1068 ◽

2014 ◽

Vol 133 (2) ◽

pp. AB404 ◽

Cited By ~ 2

Author(s):

Thomas R.M. Bieber ◽

Diamant Thaci ◽

Neil Graham ◽

Gianluca Pirozzi ◽

Ariel Teper ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Double Blind ◽

The oral Janus kinase/spleen tyrosine kinase inhibitorASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

British Journal of Dermatology ◽

10.1111/bjd.17932 ◽

2019 ◽

Vol 181 (4) ◽

pp. 733-742 ◽

Cited By ~ 28

Author(s):

R. Bissonnette ◽

C. Maari ◽

S. Forman ◽

N. Bhatia ◽

M. Lee ◽

...

Keyword(s):

Atopic Dermatitis ◽

Tyrosine Kinase ◽

Systemic Inflammation ◽

Janus Kinase ◽

Controlled Study ◽

Spleen Tyrosine Kinase ◽

Double Blind ◽

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Hwangryunhaedoktang in adult patients with Atopic Dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial - study protocol

BMC Complementary and Alternative Medicine ◽

10.1186/1472-6882-11-68 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 16

Author(s):

Nam-Kwen Kim ◽

Dong-Hyo Lee ◽

Hyung-Sik Seo ◽

Seung-Ho Sun ◽

Yong-Leol Oh ◽

...

Keyword(s):

Atopic Dermatitis ◽

Study Protocol ◽

Adult Patients ◽

Double Blind ◽

Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial

British Journal of Dermatology ◽

10.1111/j.1365-2133.1993.tb03170.x ◽

1993 ◽

Vol 129 (4) ◽

pp. 422-430 ◽

Cited By ~ 153

Author(s):

M.S. SALEK ◽

A.Y. FINLAY ◽

D.K. LUSCOMBE ◽

B.R. ALLEN ◽

J. BERTH-JONES ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Controlled Trial ◽

Double Blind ◽

Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.56 ◽

2021 ◽

Vol 5 (6) ◽

pp. s56

Author(s):

Thomas Bieber ◽

Lisa Beck ◽

Andrew Pink ◽

Hidehisa Saeki ◽

Lawrence Eichenfeld ◽

...

Keyword(s):

Atopic Dermatitis ◽

Microbial Diversity ◽

Controlled Trial ◽

Adult Patients ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

N/A

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct04090229 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study